260 related articles for article (PubMed ID: 36647006)
41. The effect of erenumab on brain network function in episodic migraine patients: a randomized, placebo-controlled clinical trial (RESET BRAIN).
Filippi M; Messina R; Bartezaghi M; Cetta I; Colombo B; Grazzi L; Martinelli D; Ornello R; Pichiecchio A; Raimondi D; Russo A; Sacco S; Splendiani A; Tassorelli C; Turrini R; Valsasina P; Rocca MA;
J Neurol; 2023 Nov; 270(11):5600-5612. PubMed ID: 37550498
[TBL] [Abstract][Full Text] [Related]
42. Initial experience with novel CGRP-receptor inhibitor therapy in Migraine in the United Arab Emirates: a retrospective observational study.
Dinh BBK; Aziz WH; Terruzzi A; Krieger DW
BMC Neurol; 2021 Dec; 21(1):486. PubMed ID: 34906111
[TBL] [Abstract][Full Text] [Related]
43. Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing-off of erenumab within monthly treatment cycle.
Dodick DW; Blumenfeld AM; Halker Singh RB; Williams R; Zhang F; Chen PW; Hsu CP; Peng C; Snellman J; Chehrenama M; Ailani J
Headache; 2023 Feb; 63(2):233-242. PubMed ID: 36226464
[TBL] [Abstract][Full Text] [Related]
44. Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data.
Guerzoni S; Baraldi C; Pensato U; Favoni V; Lo Castro F; Cainazzo MM; Cevoli S; Pani L
Neurol Sci; 2022 Jun; 43(6):3823-3830. PubMed ID: 35015202
[TBL] [Abstract][Full Text] [Related]
45. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
Tepper S; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein S; Winner P; Leonardi D; Mikol D; Lenz R
Lancet Neurol; 2017 Jun; 16(6):425-434. PubMed ID: 28460892
[TBL] [Abstract][Full Text] [Related]
46. Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials.
Tepper SJ; Ashina M; Reuter U; Hallström Y; Broessner G; Bonner JH; Picard H; Cheng S; Chou DE; Zhang F; Klatt J; Mikol DD
J Headache Pain; 2021 Jul; 22(1):81. PubMed ID: 34301173
[TBL] [Abstract][Full Text] [Related]
47. Timing and durability of response to erenumab in patients with chronic migraine.
Tepper SJ; Lucas S; Ashina M; Schwedt TJ; Ailani J; Scanlon J; Klatt J; Chou DE; Wang A; Paiva da Silva Lima G
Headache; 2021 Sep; 61(8):1255-1263. PubMed ID: 34363708
[TBL] [Abstract][Full Text] [Related]
48. Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real-world evidence.
Khalil M; Moreno-Ajona D; Villar-Martínez MD; Greenwood F; Hoffmann J; Goadsby PJ
Eur J Neurol; 2022 Aug; 29(8):2473-2480. PubMed ID: 35445471
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2-4 Prior Preventive Treatments Had Failed: LIBERTY 3-Year Study.
Reuter U; Goadsby PJ; Ferrari MD; Da Silva Lima GP; Mondal S; Kalim J; Hasan F; Wen S; Arkuszewski M; Pandhi S; Stites T; Lanteri-Minet M
Neurology; 2024 May; 102(10):e209349. PubMed ID: 38669638
[TBL] [Abstract][Full Text] [Related]
50. Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine.
Ford JH; Kurth T; Starling AJ; Ayer DW; Wietecha LA; Port MD; Rettiganti M; Ruff DD
Headache; 2020 Nov; 60(10):2304-2319. PubMed ID: 33249580
[TBL] [Abstract][Full Text] [Related]
51. Real-world effectiveness and safety of erenumab for the treatment of migraine: A systematic review and meta-analysis.
Fernández-Bravo-Rodrigo J; Cavero-Redondo I; Lucerón-Lucas-Torres M; Martínez-García I; Flor-García A; Barreda-Hernández D; Pascual-Morena C
Eur J Pharmacol; 2024 Aug; 976():176702. PubMed ID: 38823758
[TBL] [Abstract][Full Text] [Related]
52. A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults.
Sakai F; Takeshima T; Tatsuoka Y; Hirata K; Lenz R; Wang Y; Cheng S; Hirama T; Mikol DD
Headache; 2019 Nov; 59(10):1731-1742. PubMed ID: 31612482
[TBL] [Abstract][Full Text] [Related]
53. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy.
Mullin K; Kudrow D; Croop R; Lovegren M; Conway CM; Coric V; Lipton RB
Neurology; 2020 May; 94(20):e2121-e2125. PubMed ID: 31932515
[TBL] [Abstract][Full Text] [Related]
54. Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a
Lipton RB; Tepper SJ; Silberstein SD; Kudrow D; Ashina M; Reuter U; Dodick DW; Zhang F; Rippon GA; Cheng S; Mikol DD
Cephalalgia; 2021 Jan; 41(1):6-16. PubMed ID: 33269951
[TBL] [Abstract][Full Text] [Related]
55. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
Diener HC; Bussone G; Van Oene JC; Lahaye M; Schwalen S; Goadsby PJ;
Cephalalgia; 2007 Jul; 27(7):814-23. PubMed ID: 17441971
[TBL] [Abstract][Full Text] [Related]
56. Predictors of response to erenumab after 12 months of treatment.
Baraldi C; Castro FL; Cainazzo MM; Pani L; Guerzoni S
Brain Behav; 2021 Aug; 11(8):e2260. PubMed ID: 34268907
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of erenumab in women with a history of menstrual migraine.
Pavlovic JM; Paemeleire K; Göbel H; Bonner J; Rapoport A; Kagan R; Zhang F; Picard H; Mikol DD
J Headache Pain; 2020 Aug; 21(1):95. PubMed ID: 32746775
[TBL] [Abstract][Full Text] [Related]
58. Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.
Takeshima T; Sakai F; Hirata K; Imai N; Matsumori Y; Yoshida R; Peng C; Cheng S; Mikol DD
Headache; 2021 Jun; 61(6):927-935. PubMed ID: 34153117
[TBL] [Abstract][Full Text] [Related]
59. Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study.
Cainazzo MM; Baraldi C; Ferrari A; Lo Castro F; Pani L; Guerzoni S
Neurol Sci; 2021 Oct; 42(10):4193-4202. PubMed ID: 33547541
[TBL] [Abstract][Full Text] [Related]
60. Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies.
Nsaka M; Scheffler A; Wurthmann S; Schenk H; Kleinschnitz C; Glas M; Holle D
Brain Behav; 2022 Jul; 12(7):e2662. PubMed ID: 35687795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]